Jiangsu CoWin Biotech Past Earnings Performance
Past criteria checks 0/6
Jiangsu CoWin Biotech's earnings have been declining at an average annual rate of -28.6%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 74.1% per year.
Key information
-28.6%
Earnings growth rate
-30.0%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -74.1% |
| Return on equity | -7.5% |
| Net Margin | -95.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Jiangsu CoWin Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 123 | -117 | 159 | 92 |
| 31 Dec 23 | 171 | -84 | 154 | 88 |
| 30 Sep 23 | 275 | -22 | 126 | 91 |
| 30 Jun 23 | 378 | 49 | 120 | 87 |
| 31 Mar 23 | 476 | 124 | 115 | 79 |
| 31 Dec 22 | 522 | 159 | 109 | 74 |
| 30 Sep 22 | 501 | 185 | 92 | 54 |
| 30 Jun 22 | 478 | 185 | 123 | 67 |
| 31 Mar 22 | 375 | 128 | 80 | 46 |
| 31 Dec 21 | 338 | 126 | 73 | 39 |
| 31 Dec 20 | 233 | 108 | 39 | 24 |
| 31 Dec 19 | 74 | 9 | 28 | 14 |
| 31 Dec 18 | 56 | 7 | 24 | 11 |
Quality Earnings: 688426 is currently unprofitable.
Growing Profit Margin: 688426 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688426 is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare 688426's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688426 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 688426 has a negative Return on Equity (-7.48%), as it is currently unprofitable.